2022/04/21 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Singapore (IPOS), Application No. 11201901294Q. Post author:alarpharm Post published:21 . 4 . 2022 Post category:Media releases You Might Also Like 2022/01/13 Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 14 . 1 . 2022 2022/05/06 ALA-1000 Received notice of patent allowance from Intellectual Property Office of India , Application No. 201947006642 9 . 5 . 2022 2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021 2020/08/03 ALA -1000 Receive notice of patent allowance from the IP Australia. 25 . 8 . 2020 2020/07/22 ALA -1000 Receive notice of patent allowance from the Mexican Institute of Industrial Property (IMPI) 13 . 8 . 2020
2022/01/13 Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 14 . 1 . 2022
2022/05/06 ALA-1000 Received notice of patent allowance from Intellectual Property Office of India , Application No. 201947006642 9 . 5 . 2022
2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021
2020/07/22 ALA -1000 Receive notice of patent allowance from the Mexican Institute of Industrial Property (IMPI) 13 . 8 . 2020
